• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SINTX Technologies Provides Positive Strategic Business Update for Q3 2024

    11/14/24 6:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care
    Get the next $SINT alert in real time by email

    Salt Lake City, UT, Nov. 14, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications, announced today a positive update on its recent strategic initiatives and financial performance, showcasing the Company's commitment to realigning its resources and achieving long-term growth.

    In line with its ongoing evaluation of a change in strategic emphasis, SINTX continues to restructure its operations to focus on high-impact, sustainable markets in the medical device industry. This transition aims to leverage the unique properties of SINTX's silicon nitride and other advanced materials, renowned for their durability, biocompatibility, and antimicrobial properties, to drive innovations in spinal fusion devices, orthopedic implants, and surgical tools. The Company is also actively pursuing partnerships and collaborations with healthcare institutions and industry leaders to bring novel solutions to the medical community.

    Eric Olson, CEO of SINTX Technologies, commented, "We remain committed to maximizing shareholder value by channeling resources towards markets with substantial growth potential and focusing on product innovations that meet the unmet needs in healthcare."

    In the third quarter of 2024, the Company made difficult, but essential, decisions to align with its renewed focus. Notably, SINTX made the decision to cease operations of its armor division and recorded a one-time $4.5 million impairment charge. This move aligns with SINTX's emphasis on reallocating resources towards the medical device market, where the Company sees the greatest potential for impactful, sustainable growth. Additionally, a reduction in workforce during Q3 positions the company for a leaner, more efficient structure, supporting ongoing cost optimization efforts.

    SINTX also reported significant improvement in liquidity, closing the quarter with $4.8 million in cash, up from $3.3 million at year-end 2023, fueled by strategic offerings that raised $9.4 million year-to-date. These funds will help strengthen SINTX's financial position as it continues to execute its transformation strategy.

    During the third quarter of 2024, SINTX achieved growth in revenue, with an 18% total increase in the same quarter last year. This improvement reflects heightened demand for SINTX's high-tech ceramics in biomedical and industrial applications.

    Looking ahead, SINTX remains focused on further expanding its footprint in the medical device sector. The Company is currently exploring new collaborations with strategic advisory partners to evaluate potential merger candidates, acquisitions, strategic partners and sale of business divisions, which could support SINTX's ambitions to become a leader in the medical device market.

    For more information, please visit www.sintx.com

    About SINTX Technologies, Inc.

    SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter new markets. The Company has manufacturing and R&D facilities in Utah and Maryland. For more information on SINTX Technologies or its materials platform, visit www.sintx.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA") that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding advancement of ceramic technologies and exploring new avenues for growth and innovation, and the potential to pursue growth opportunities and explore strategic opportunities.

    Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, difficulty in commercializing ceramic technologies and development of new product opportunities. A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 27, 2024, and in SINTX's other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law.

    Business and Media Inquiries for SINTX:

    SINTX Technologies

    801.839.3502

    [email protected]



    Primary Logo

    Get the next $SINT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SINT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SINT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Trask Kevin

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/10/26 8:45:54 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chairman, President and CEO Olson Eric K.

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/10/26 8:44:43 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Investment Officer Honigblum Gregg R.

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/10/26 8:43:48 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    SEC Filings

    View All

    SEC Form EFFECT filed by SiNtx Technologies Inc.

    EFFECT - Sintx Technologies, Inc. (0001269026) (Filer)

    12/12/25 12:15:20 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form S-3/A filed by SiNtx Technologies Inc.

    S-3/A - Sintx Technologies, Inc. (0001269026) (Filer)

    12/9/25 5:01:07 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SiNtx Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Sintx Technologies, Inc. (0001269026) (Filer)

    12/1/25 8:35:26 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Investment Officer Honigblum Gregg R. bought $34,896 worth of shares (8,200 units at $4.26), increasing direct ownership by 4% to 201,067 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    12/9/25 8:00:05 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Chief Investment Officer Honigblum Gregg R. bought $255,350 worth of shares (65,000 units at $3.93) and was granted 53,867 shares, increasing direct ownership by 161% to 192,867 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    12/8/25 8:00:03 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Chief Investment Officer Honigblum Gregg R. bought $31,900 worth of shares (10,000 units at $3.19), increasing direct ownership by 16% to 74,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    11/10/25 8:00:06 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SINTX Technologies to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference on February 4–5

    SALT LAKE CITY, Utah, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon-nitride-based medical technologies, today announced that its management team will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference, to be held February 4–5, 2026. The Company's participation comes at an important stage in its evolution, following a period of operational restructuring, enhanced financial discipline, and a renewed strategic focus on its core medical-technology platforms. With a more streamlined cost structure, greater visibility into its balance-sheet, and sev

    1/29/26 9:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies to Participate in Sidoti & Company Investor Conference

    SALT LAKE CITY, Utah, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), today announced that management will be presenting at Sidoti & Company's Year End Virtual Investor Conference, held December 10-11, 2025. Sidoti's Year End Virtual Investor ConferenceDates: December 10-11, 2025Presentation Date and Time: Wednesday, December 10, 2025 at 3:15 P.M. ETWebcast: https://sidoti.zoom.us/webinar/register/WN_O_OnAvXpQki63dk_9JbUYw To schedule a one-on-one meeting with SINTX Technologies' management team, please email KCSA Strategic Communications at [email protected]. To be added to the Sintx Technologies email distribution list, please email Si

    12/8/25 9:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants

    Milestone enables immediate production of SiN/PEEK custom devices SALT LAKE CITY, Utah, Dec. 01, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company, today announced that it has signed a supply agreement with Evonik Corporation ("EVONIK"), a global leader in high‑performance polymers, to manufacture the Company's proprietary silicon nitride–PEEK compound (SiN/PEEK) (U.S. Patent No. 10,806,831) engineered for AI‑assisted additive manufacturing of patient‑specific implants that will be produced using equipment already in place at SINTX's U.S.-based production facility. Under the agreement, EVONIK will pr

    12/1/25 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    11/14/24 7:25:52 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by SiNtx Technologies Inc.

    SC 13G - Sintx Technologies, Inc. (0001269026) (Subject)

    4/1/24 4:17:43 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by SiNtx Technologies Inc. (Amendment)

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    2/13/24 8:12:54 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Financials

    Live finance-specific insights

    View All

    SINTX Reports Pivotal Third Quarter Business Update and Financial Highlights Driven by FDA Clearance, Product and IP Portfolio Expansions and Increased Operational Efficiencies

    Company underscores its strengthened liquidity, cost reductions, and first revenue recorded from OsseoSculpt™  SALT LAKE CITY, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon-nitride–based medical technologies, today provided a business update reporting third quarter financial results in conjunction with the filing the Company's Form 10-Q for the quarter ended September 30, 2025. During the third quarter and subsequent weeks, SINTX advanced a focused commercialization plan centered on infection-resistant silicon nitride devices and polymer composites, while tighteni

    11/13/25 8:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market

    Strategic Acquisition Brings Patented Implant Designs, Seasoned Executive Team, and Near-Term Commercial Opportunities SALT LAKE CITY, Utah, June 24, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company focused on medical device innovation, today announced that it has executed a Definitive Agreement to acquire the surgical business assets of SiNAPTIC Holdings, LLC, a privately held company focused on silicon nitride ceramic manufacturing and innovation. This transaction is a significant milestone in SINTX's strategy to acquire a potential competitor and drive commercial revenue growth and expand its product portfolio in t

    6/24/25 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Acquires Technology Assessment and Transfer, Inc.

    The Acquisition Broadens Opportunities for SINTX in Aerospace, Defense, and Biomedical Markets SALT LAKE CITY, July 06, 2022 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ:SINT) ("SINTX" or the "Company"), an original equipment manufacturer of advanced ceramics, announced the acquisition of Technology Assessment and Transfer, Inc. (TA&T; https://www.techassess.com/), significantly increasing SINTX's capabilities in the aerospace, defense, and biomedical markets. "We are excited to acquire TA&T and take another step towards diversifying and strengthening SINTX," said Dr. Sonny Bal, President and CEO of SINTX. "TA&T will expand our use of advanced manufacturing techno

    7/6/22 9:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Leadership Updates

    Live Leadership Updates

    View All

    SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer

    Seasoned Healthcare Executive to Lead Strategic Growth Initiatives Salt Lake City, UT, Nov. 19, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications, is pleased to announce the appointment of Gregg R. Honigblum as Chief Strategy Officer (CSO). In this role, Mr. Honigblum will oversee driving corporate strategy to support SINTX's growth initiatives and enhancing investor relations. Mr. Honigblum brings over 35 years of experience as an executive for emerging growth companies, specializing in the healthcare secto

    11/19/24 6:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care